Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastroenterology

Title: Gastroenterology

ISSN (Electronic): 1528-0012

ISSN (Print): 0016-5085

Publication date (Electronic): Jun 2016

Volume: 150

Issue: 7

Affiliations

[1 ] Division of Gastroenterology/Hepatology, Scripps Clinic and Scripps Translational Science Institute, La Jolla, California.

[2 ] Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania.

[3 ] The Liver Institute at Methodist Dallas, Dallas, Texas.

[4 ] Infectious Disease Development, AbbVie Inc, North Chicago, Illinois.

[5 ] Medical Associates Research Group, San Diego, California.

[6 ] Division of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins University, Baltimore, Maryland.

[7 ] Division of Gastroenterology, North Shore University Hospital, Manhasset, New York.

[8 ] Global Pharmaceutical Development, AbbVie Inc, North Chicago, Illinois.

[9 ] Statistics and Computer Sciences, AbbVie Inc, North Chicago, Illinois.

[10 ] Clinical Pharmacokinetics, AbbVie Inc, North Chicago, Illinois.

[11 ] Department of Gastroenterology, The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas. Electronic address: lawitz@txliver.com.

Article

Publisher Item ID: S0016-5085(16)00326-7

DOI: 10.1053/j.gastro.2016.02.078

PubMed ID: 26976799

SO-VID: 1e84d761-841a-426e-ac0d-085775f76fd8

History

Keywords: NS3/4A Protease Inhibitor,NS5A Inhibitor,RUBY-I,Renal Disease

Data availability:

Keywords: NS3/4A Protease Inhibitor, NS5A Inhibitor, RUBY-I, Renal Disease

Comments

Comment on this article

Cited by 73

See all cited by